Qwell Pharmaceuticals

Quell Therapeutics is a clinical-stage biotechnology company based in London, focused on developing engineered T-regulatory (Treg) cell therapies for autoimmune and inflammatory diseases, as well as transplantation. The company utilizes its proprietary multi-modular Treg platform to create therapies designed to restore immune balance and induce durable immune tolerance. Its lead candidate, QEL-001, is currently in Phase 1/2 clinical development for the prevention of organ rejection in liver transplant patients. Quell has established a major strategic partnership with AstraZeneca to advance Treg therapies for Type 1 Diabetes and Inflammatory Bowel Disease, highlighting the potential of its platform in large-market indications.